reports
Dexcom Reports First Quarter 2024 Financial Results
SAN DIEGO--(BUSINESS WIRE)-- DexCom, Inc. (Nasdaq: DXCM) today reported its financial results as of and for the quarter ended March 31, 2024. First Quarter 2024 Financial Highlights: Revenue grew 24% year-over-year to $921.0 million on a reported basis and 25% year-over-year on an organic1 basis. U.S. revenue and international revenue both grew 24% on a reported basis and international revenue grew 26% on an organic1 basis, all on a year-over-year basis. GAAP operating income of $101.1 million or 11.0% of revenue, an increase of 460 basis points compared to the first quarter of 2023...
- Dave Nicoski
- Ross LaDuke
Vital Signs: Actionable charts
In this product we rank the most positive and negative domestic stocks, filter the symbols by market-cap and trading volume, and then divide the companies into sectors and groups. We then manually look through charts leadership/changes, bottoms-up/top-down ideas, short-term patterns that may have long-term significance, etc. We believe you will find this product valuable as significant price and relative moves begin in the daily charts.
PEP PEPSICO INC.
TXN TEXAS INSTRUMENTS INCORPORATED
TRMK TRUSTMARK CORPORATION
SWN SOUTHWESTERN ENERGY COMPANY
SMTC SEMTECH CORPORATION
SATS ECHOSTAR CORPORATION CLASS A
RRC RANGE RESOURCES CORPORATION
NFG NATIONAL FUEL GAS COMPANY
MDWD MEDIWOUND
LWAY LIFEWAY FOODS INC.
HAS HASBRO INC.
FBP FIRST BANCORP
EQT EQT CORPORATION
DECK DECKERS OUTDOOR CORPORATION
CRK COMSTOCK RESOURCES INC.
VIRT VIRTU FINANCIAL INC. CLASS A
SYF SYNCHRONY FINANCIAL
HRTG HERITAGE INSURANCE HOLDINGS INC.
BSX. BELO SUN MINING CORP.
ORN ORION GROUP HOLDINGS
ITGR INTEGER HOLDINGS CORPORATION
PE. PURE ENERGY MINERALS LTD
DESP DESPEGAR.COM CORP.
AMRX AMNEAL PHARMACEUTICALS INC. CLASS A
NTB BANK OF N.T. BUTTERFIELD & SON
COOP MR. COOPER GROUP INC.
KTB KONTOOR BRANDS
ALXO ALX ONCOLOGY HOLDINGS
PRDO PERDOCEO EDUCATION CORP
LRN STRIDE INC
PRG PROG HOLDINGS INC
VRT VERTIV HOLDINGS CO (A)
AMAL AMALGAMATED FINANCIAL CORP
CGEM CULLINAN ONCOLOGY INC
RANI RANI THERAPEUTICS HLDGS INC
CR CRANE CO NEW
BGC BGC GROUP INC
SOWG SOW GOOD INC COM
Dexcom Inc: 1 director
A director at Dexcom Inc sold 49,633 shares at 138.298USD and the significance rating of the trade was 72/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly sho...
Dexcom Publishes Annual Sustainability Report
SAN DIEGO--(BUSINESS WIRE)-- (NASDAQ:DXCM), the leader in real-time continuous glucose monitoring (CGM) for people with diabetes, today released its annual Sustainability Report. This report provides updates on key corporate sustainability initiatives that are aligned with Dexcom’s core values and business strategy. “We are always working to advance the interests of our stakeholders, including our global customer base, employees and their families, caregivers, our communities, and our shareholders,” said Kevin Sayer, chairman, president and CEO of Dexcom. “We see an inherent connection betw...
Dexcom Schedules First Quarter 2024 Earnings Release and Conference Ca...
SAN DIEGO--(BUSINESS WIRE)-- (NASDAQ:DXCM) today announced that it plans to release its first quarter 2024 financial results after market close on Thursday, April 25, 2024. Management will hold a conference call to review the company's first quarter 2024 performance starting at 4:30 p.m. (Eastern Time) on the same day. The conference call will be concurrently webcast. The link to the webcast will be available on the Dexcom investor relations website at and will be archived there for future reference. To listen to the conference call, please dial (877) 344-3040 (US/Canada) or (646) 475-1647...
Stelo by Dexcom First Glucose Biosensor to be Cleared by FDA as Over-t...
SAN DIEGO--(BUSINESS WIRE)-- (NASDAQ:DXCM), the global leader in real-time continuous glucose monitoring for people with diabetes, announced today that the FDA has cleared Stelo by Dexcom – the first glucose biosensor that doesn’t require a prescription. There are approximately 25 million people in the U.S. living with Type 2 diabetes who do not use insulin and who can benefit from continuous glucose monitoring (CGM) technology. Today, Dexcom G7 is available for them with a prescription. Stelo, cleared for use without a prescription, will make it even easier for this population to access lead...
Dexcom Showcases Leadership in AID and Power of Dexcom CGM in Type 2 D...
EDINBURGH, Scotland--(BUSINESS WIRE)-- DexCom, Inc. (NASDAQ: DXCM), the global leader in real-time continuous glucose monitoring (CGM) for people with diabetes, announced compelling new clinical evidence supporting the use of Dexcom continuous glucose monitoring (CGM) for automated insulin delivery (AID) systems. Dexcom also announced data showcasing the significant benefits of CGM use for individuals managing Type 2 diabetes, along with groundbreaking evidence demonstrating a direct association between CGM use and reduced mortality in people with Type 1 and Type 2 diabetes. The evidence and d...
Dexcom Announces Upcoming Conference Presentation
SAN DIEGO--(BUSINESS WIRE)-- (NASDAQ:DXCM) today announced that Sean Christensen, Vice President, Finance and Investor Relations, will present an update on the company at the 45th Annual Raymond James Institutional Investors Conference on Tuesday, March 5th. The live presentation is scheduled to begin at approximately 8:40 AM EST and will be concurrently webcast. Links to the webcast will be available on the Dexcom Investor Relations website at and will be archived there for future reference. About DexCom, Inc. DexCom, Inc. empowers people to take real-time control of health through ...
- Dave Nicoski
- Ross LaDuke
Vital Signs: Actionable charts
In this product we rank the most positive and negative domestic stocks, filter the symbols by market-cap and trading volume, and then divide the companies into sectors and groups. We then manually look through charts leadership/changes, bottoms-up/top-down ideas, short-term patterns that may have long-term significance, etc. We believe you will find this product valuable as significant price and relative moves begin in the daily charts.
WTM WHITE MOUNTAINS INSURANCE GROUP LTD
TXRH TEXAS ROADHOUSE INC.
TNET TRINET GROUP INC.
MCY MERCURY GENERAL CORPORATION
EIG EMPLOYERS HOLDINGS INC.
CHEF CHEFS WAREHOUSE HOLDINGS
CAMT CAMTEK LTD.
QUAD QUAD/GRAPHICS INC. CLASS A
DNOW NOW INC.
GES GUESS? INC.
PVH PVH CORP.
USPH U.S. PHYSICAL THERAPY INC.
FONR FONAR CORP.
UIHC UNITED INSURANCE HOLDINGS CORP.
KNSL KINSALE CAPITAL GROUP INC.
TSEM TOWER SEMICONDUCTOR LTD
GLOB GAZIT-GLOBE LTD.
NOTV INOTIV INC
ABSI ABSCI CORP
RXST RXSIGHT INC
BLZE BACKBLAZE INC
COIN COINBASE GLOBAL INC
SERA SERA PROGNOSTICS INC
WGS ONTO INNOVATION INC.
BGC GENEDX HOLDINGS CORP.
DAVE BGC GROUP INC
VNOM DAVE INC
VIPER ENERGY INC
Dexcom Reports Fourth Quarter and Fiscal Year 2023 Financial Results
SAN DIEGO--(BUSINESS WIRE)-- (Nasdaq: DXCM) today reported its financial results as of and for the quarter and fiscal year ended December 31, 2023. Fourth Quarter 2023 Financial Highlights: Revenue grew 27% versus the same quarter of the prior year to $1.03 billion on a reported basis and 26% on an organic1 basis. U.S. revenue growth of 27% and international revenue growth of 27% on a reported basis. International revenue growth was 23% on an organic1 basis. GAAP operating income of $216.9 million or 21.0% of revenue, an increase of 560 basis points compared to the fourth quarter o...
Dexcom Schedules Fourth Quarter and Fiscal Year 2023 Earnings Release ...
SAN DIEGO--(BUSINESS WIRE)-- (NASDAQ:DXCM) today announced that it plans to release its fourth quarter and fiscal year 2023 financial results after market close on Thursday, February 8, 2024. Management will hold a conference call to review the company's fourth quarter and fiscal year 2023 performance starting at 4:30 p.m. (Eastern Time) on the same day. The conference call will be concurrently webcast. The link to the webcast will be available on the Dexcom investor relations website at and will be archived there for future reference. To listen to the conference call, please dial (888) 41...
Dexcom Secures Future in Europe, Middle East, and Africa by Breaking G...
GALWAY, Ireland--(BUSINESS WIRE)-- (Nasdaq: DXCM), a global leader in real-time continuous glucose monitoring (rtCGM) for people with diabetes, has officially broken ground on its new state-of-the-art manufacturing facility, located in Athenry, Co. Galway. This marks the first step in the realisation of this facility, which will bring more than 1,000 jobs to the area and represents one of the biggest single private sector investments ever in the West of Ireland. Dexcom’s first manufacturing facility in Europe will ensure the flow of products throughout EMEA, with the potential to lower the ...
A Powerful Alliance: Dexcom G7 Now Connects to Tandem t:slim X2
EDINBURGH, Scotland--(BUSINESS WIRE)-- (Nasdaq: DXCM), a global leader in real-time continuous glucose monitoring for people with diabetes, announced today the Dexcom G7 Continuous Glucose Monitoring (CGM) System now connects with the t:slim X2™ insulin pump by Tandem Diabetes Care in countries across Europe and in South Africa. The announcement comes just a month after the system launched in the United States and combines the power and accuracy of Dexcom G7 with the discretion of the Tandem t:slim X2. “For over a decade Dexcom has been pioneering industry leading CGM connectivity, meaning ...
Dexcom Reports Preliminary, Unaudited Revenue for the Fourth Quarter a...
SAN DIEGO--(BUSINESS WIRE)-- (Nasdaq: DXCM), the leader in real-time continuous glucose monitoring (“CGM”), today reported that it expects preliminary, unaudited revenue for the fourth quarter ended December 31, 2023 to be at least $1.030 billion, an increase of 26% over the fourth quarter of 2022. U.S. revenue is expected to be approximately $765 million, representing growth of 26% over the fourth quarter of 2022. International revenue is expected to be approximately $265 million, an increase of 27% over the fourth quarter of 2022. For fiscal 2023, total preliminary, unaudited revenue is e...
Dexcom to Present at 42nd Annual J.P. Morgan Healthcare Conference
SAN DIEGO--(BUSINESS WIRE)-- (NASDAQ:DXCM) today announced that Kevin Sayer, Chairman, President and Chief Executive Officer, will present an update on the company at the 42nd annual J.P. Morgan Healthcare Conference on January 8, 2024. The live presentation is scheduled to begin at approximately 12:45 PM EST and will be concurrently webcast. Links to the webcast will be available on the Dexcom Investor Relations website at and will be archived there for future reference. About DexCom, Inc. DexCom, Inc. empowers people to take real-time control of health through innovative continuous...
Dexcom G7, the Smallest, Most Accurate, Easy-to-Use CGM Now Connects t...
SAN DIEGO--(BUSINESS WIRE)-- (Nasdaq: DXCM), the global leader in real-time continuous glucose monitoring for people with diabetes, the Dexcom G7 Continuous Glucose Monitoring (CGM) System with the t:slim X2™ insulin pump by Tandem Diabetes Care in the United States, marking the first AID integration with the Dexcom G7 CGM, the world’s most accurate1,2 CGM system. This press release features multimedia. View the full release here: Dexcom G7 CGM now connects with the t:slim X2™ insulin pump by Tandem Diabetes Care in the U.S. (Photo: Business Wire) “There’s a reason Dexcom is the undisputed...
Dexcom Announces Upcoming Conference Presentation
SAN DIEGO--(BUSINESS WIRE)-- (NASDAQ:DXCM) today announced that Jereme Sylvain, Executive Vice President and Chief Financial Officer, will present an update on the company at the Piper Sandler 35th Annual Healthcare Conference on Wednesday, November 29th. The live presentation is scheduled to begin at approximately 8:30 AM EST and will be concurrently webcast. Links to the webcast will be available on the Dexcom Investor Relations website at and will be archived there for future reference. About DexCom, Inc. DexCom, Inc. empowers people to take real-time control of health through inn...
Dexcom dévoile une galerie de portraits pour dépeindre les hauts et le...
SAN DIEGO et ÉDIMBOURG, Écosse--(BUSINESS WIRE)-- (NASDAQ : DXCM), le chef de file mondial des systèmes de surveillance continue du glucose (CGM) en temps réel pour les personnes atteintes de diabète, fait équipe avec à l'échelle mondiale pour aider à sensibiliser à la nécessité d’améliorer l’accès aux technologies qui changent la vie en matière de gestion du diabète durant le Mois national de sensibilisation au diabète aux États-Unis et au Canada (novembre) et à l’occasion de la Journée mondiale du diabète (14 novembre). Ce communiqué de presse contient des éléments multimédias. Voir le co...
Dexcom Unveils Portrait Gallery to Portray Emotional Highs and Lows of...
SAN DIEGO & EDINBURGH, Scotland--(BUSINESS WIRE)-- (NASDAQ: DXCM), the global leader in real-time continuous glucose monitoring (CGM) systems for people with diabetes, is teaming up with from around the globe to help raise awareness for the need to improve access to life-changing diabetes technology during National Diabetes Awareness Month in the U.S. and Canada (November) and on World Diabetes Day (November 14). This press release features multimedia. View the full release here: Dexcom Warriors from top left to right: Bambi B., Enrrique A., Nenad Š., Qiana D. & Lily D., Nick J. Dexcom War...
Historic Victory as People With Diabetes Win Access to Life-Changing T...
LONDON--(BUSINESS WIRE)-- DexCom, Inc. (NASDAQ: DXCM), a global leader in real-time continuous glucose monitoring (rtCGM) for people with diabetes, announced today new market research which found 79% of people struggle to keep their glucose levels in range, and that almost half (45%) don’t understand what a Hybrid Closed Loop System (HCL) is or how HCL could benefit them1-2. Findings also showed that 99% of healthcare providers expect the NICE TA for HCL systems will somewhat or significantly help change the lives of people living with type 1 diabetes for the better1-2. Dexcom’s research fol...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.